On April 5, 2016, the FDA approved Celltrion's application to market a biosimilar to Janssen Biotech Inc.'s REMICADE® (infliximab) anti-TNF-a antibody (see "FDA Approves Inflectra - Celltrion's REMICADE® Biosimilar"). ...more
10/20/2016
/ Biosimilars ,
Biotechnology ,
Celltrion ,
Food and Drug Administration (FDA) ,
Obviousness ,
Patent Expiration ,
Patent Infringement ,
Patent Invalidity ,
Patents ,
Pfizer ,
Pharmaceutical Industry